Cuts of up to 99% are authorized in Medicare drug reimbursements

Why This Topic Matters

The article addresses a potentially major shift in Medicare drug reimbursement that could affect practice revenue, drug acquisition costs, and administration payment policies. It also highlights how federal agencies and Congress were responding to concerns about underpayment for certain specialty drugs.

Article Sections

1. Medicare reimbursement review and proposed drug payment changes

   Overview of the policy action involving Medicare-covered office-administered drugs and a government pricing review. Summarizes the broad reimbursement issue and the agency response.

2. Drugs shielded from the proposed cuts

   Discussion of the subset of drugs that were not included in the payment reduction approach. Covers the broader policy considerations affecting oncology and hemophilia-related therapies.

3. Examples of authorized cuts and implementation timing

   Illustrative examples of how the pricing review could affect selected drugs, along with the timing and administrative process for carrier decisions.

4. Government findings, congressional pressure, and next steps

   Background on federal audit findings, congressional concerns, and the agency’s stated plans for additional reimbursement changes and future proposals.

5. Provider perspective

   Comments from a medical practice representative about reimbursement pressures and the operational costs associated with drug preparation and administration.